Magda Marquet

Dr. Marquet is the co-Founder of ALMA Life Sciences, LLC, an early-stage investment firm focusing on the creation and growth of innovative healthcare companies with an overall focus on prevention. She is also the co-Founder of AltheaDx, a commercial-stage precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression. Dr. Marquet co-founded Althea Technologies in 1998 and led the company to the successful acquisition by Ajinomoto, a global Japanese company, leader in amino acid technology. During her tenure at Althea Technologies, Dr. Marquet had full P&L responsibility and built an organization with R&D and international commercial capabilities. Prior to starting Althea Technologies, Dr. Marquet held several positions in product development and pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. She currently serves on the following Boards: Pfenex (PFNX) where she is a member of the Governance and Nomination Committee and Arcturus Therapeutics (ARCT) where is the Chairman of the Compensation Committee and a member of the Audit Committee. She also serves on the Board of several private companies such as Senté. As a former founder and CEO, Dr. Marquet provides the Board with operational, fundraising expertise including venture, private equity, and venture debt. She also brings expertise in M&A, global commercial development, and regulatory strategies. She has a passion for building a winning culture of innovation and strategic growth. She holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum, and has been inducted into the CONNECT Entrepreneur Hall of Fame.